Ado-Trastuzumab Emtansine
Brand: Kadcyla (global) / T-DM1 (IN/BD)
Anticancer
HER2 ADC (trastuzumab + DM1)
Pharmacokinetics
| Half-life | 96 hours |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Dose: 3.6 mg/kg IV q21 days. Calculated approx eqv ~10 mg/day for PK calculator notes. Hepatic clearance — avoid in severe hepatic impairment. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Hepatotoxicity, thrombocytopenia, peripheral neuropathy, pneumonitis
Contraindications:
Severe hepatic impairment
Precautions:
Monitor LFTs & platelets. Hold therapy for Grade 3–4 liver enzyme elevation.
• half-life avg ≈ 4 days → 96 hours
• dose: 3.6 mg/kg IV q3 weeks
• we store average adult female 60 kg → ~216 mg per 3 weeks → ~216/21 ≈ 10 mg/day equivalent (similar logic we applied to others)